electrospray ionization is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-08. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
| Property | Value | Notes |
|---|---|---|
| Identity confirmation | Reversed-phase HPLC retention time versus reference standard | Retention depends on column, gradient, and ion-pairing agent |
| Mass confirmation | Electrospray or MALDI mass spectrometry | Doubly protonated ion near m/z 377 is consistent with about 752 Da |
| Typical purity specification | 95 percent or higher by chromatographic peak area | Lower values suggest truncated or modified peptide species |
| Storage of lyophilized powder | -20 °C, desiccated, protected from light | Powder tolerates long storage better than solution |
| Storage of solution | 2-8 °C for short periods | Freeze-thaw cycling promotes aggregation and surface adsorption |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Experts said that their findings did not challenge the conclusions by UK government: "We provided that information to the Government who have then used a number of other sources to come to the conclusions that they have." On 12 April 2018 the OPCW announced that their investigations agreed with the conclusions made by the UK about the identity of the chemical used. By September 2018, two Russian "tourists", "Alexander Petrov" and "Ruslan Boshirov", had been identified as suspects. They told Margarita Simonyan, the chief editor of RT television, in an interview that they both worked in the sports nutrition business and that: "Those are our real names.. We're afraid to go out, we fear for ourselves, our lives and lives of our loved ones." The Crown Prosecution Service announced enough evidence was obtained by that date "to convict the two men" of the attack, although it did not apply to Russia "for their extradition because Russia does not extradite its own nationals. [...] However, a European Arrest Warrant has been obtained in case they travel to the EU". In February 2019, the Bellingcat website published precise allegations that identified GRU Major Denis Vyacheslavovich Sergeev as a man who travelled in March 2018 to London under the false identity of Sergei Fedotov. It is claimed with detailed photograph evidence, and phone, travel, passport, and motoring database records that GRU Colonels Alexander Mishkin and Anatoly Chepiga assumed the identities of Petrov and Boshirov, and placed the poison on Skripal's doorknob.
=== History === During World War I, munitions workers in France fell ill and some died from DNP exposure. Stanford University academic Maurice L. Tainter learned of DNP's effect in raising the metabolic rate and causing weight loss and pioneered its use as a weight loss drug. Although he was aware of DNP's narrow therapeutic index, Tainter tried the drugs on obese patients and published successful results in 1933; average weight loss was 20 pounds (9.1 kg) and most recipients did not report adverse effects. In 1934, Tainter estimated that at least 100,000 people had been treated with DNP in the United States during its first year on the market and there had been three reported fatalities connected to the drug. Tainter argued that DNP was highly effective in raising the metabolic rate (up to 50 percent) and avoided the negative circulatory effects of desiccated thyroid, another weight loss drug in use at the time.
A fault on a power sub-transmission feeder causes a power shortage in the southern Far North District that affects 23,000 homes and businesses. 7 November – Local authorities in the Clutha District and Southland Region lift local states of emergency caused by the October 2025 New Zealand storms. 8 November – A wildfire breaks out in Tongariro National Park, engulfing 2,500 hectares and leading to the evacuation of campers and the closure of a nearby highway. 9 November: The wildfire in Tongariro National Park engulfs 2,500 hectares, leading to the evacuation of Whakapapa Village. Firefighters manage to contain 20% of the fire. Te Pāti Māori's national council votes overnight to expel MPs Mariameno Kapa-Kingi and Tākuta Ferris following several weeks of internal conflict. The decision is confirmed by the party's leadership the following day. The New Zealand government extends its suspension of NZ$29.8 million worth of funding to the Cook Islands over the next two financial years in response to the Cook Islands government signing several partnership agreements with China in February 2025. 10 November: The wildfire in the Tongariro National Park subsides due to rainfall and the efforts of firefighters to contain the blaze. Residents of Whakapapa Village are allowed to return. An estimated 3,000 hectares have been damaged by the wildfire. The contactless fare payment system Motu Move is launched on public buses and the ferry in Christchurch.
Sources: en.wikipedia.org
The main symptoms of RA are joint pain, swelling, and stiffness, which are usually worst in the morning or after resting. Joint affected by RA are often tender when pressed or moved. Morning stiffness can last for several hours but gradually improves with movement and physical activity.This is different from osteoarthritis, where stiffness doesn't last as long. The symptoms of RA can make it difficult to perform everyday tasks, interfere with sleep, and reduce overall quality of life. RA usually develops gradually and often begins by affecting the small joints of the hands (metacarpophalangeal and proximal interphalangeal joints) and feet before spreading to larger joints. The condition can affect any joint, tendon, or bursa that contains synovial tissue, including the elbows, shoulders, ankles, knees, hips, and jaw. RA is polyarticular, meaning it affects multiple joints. Although RA usually affects the same joints on both sides of the body, this symmetry may not be present in the early stages. RA can be difficult to detect when it first develops because inflammation of the synovial membrane (synovitis) may not be visible early on. Signs of synovitis include soft, spongy swelling around a joint. Joint deformities are not seen early in the disease but can develop over time if RA is severe, chronic, or left untreated, and can potentially lead to significant disability. As the pathology progresses, the inflammatory activity leads to tendon tethering and erosion and destruction of the joint surface, which impairs range of movement and leads to deformity.
=== Acute toxicity === Melamine is reported to have an oral median lethal dose (LD50) of 3248 mg/kg based on rat data. It is also an irritant when inhaled or in contact with the skin or eyes. The reported dermal LD50 is greater than 1000 mg/kg for rabbits. A study by Soviet researchers in the 1980s suggested that melamine cyanurate, commonly used as a fire retardant, could be more toxic than either melamine or cyanuric acid alone. For rats and mice, the reported LD50 for melamine cyanurate was 4.1 g/kg (given inside the stomach) and 3.5 g/kg (via inhalation), compared to 6.0 and 4.3 g/kg for melamine and 7.7 and 3.4 g/kg for cyanuric acid respectively. A toxicology study in animals conducted after recalls of contaminated pet food concluded that the combination of melamine and cyanuric acid in diet does lead to acute kidney injury in cats. A 2008 study produced similar experimental results in rats and characterized the melamine and cyanuric acid in contaminated pet food from the 2007 outbreak. A 2010 study from Lanzhou University attributed kidney failure in humans to uric acid stone accumulation after ingestion of melamine resulting in a rapid aggregation of metabolites such as cyanuric acid diamide (ammeline) and cyanuric acid. A 2013 study demonstrated that melamine can be metabolized to cyanuric acid by gut bacteria. In particular, Klebsiella terrigena was determined to be a factor in melamine toxicity. In culture, K. terrigena was shown to convert melamine to cyanuric acid directly.
== Legacy == Robert Swanson's legacy can still be found to this day through the company he cofounded and led. Genentech continues to develop and produce therapeutic drugs, and some of his policies, such as allowing company scientists to publish, are still in place. Genentech scored many firsts under Swanson's leadership, such as developing the first drug produced via genetic engineering, being the first biotechnology company to go public, and being the first biotechnology company to sell its own drug. These accomplishments have earned Genentech, and Swanson, a place in the history of the biotechnology industry.
Sources: en.wikipedia.org
Identity is confirmed by matching the retention time in reversed-phase chromatography against a reference standard and by measuring the molecular mass with mass spectrometry. Tandem mass spectrometry or amino acid analysis can verify the sequence of the seven residues. Because the peptide contains no aromatic amino acids, detection at 280 nm is not useful.
Lyophilized powder is normally stored desiccated at -20 °C, protected from light and moisture. Powder kept under these conditions is generally stable for long periods. Solutions are less stable and are usually prepared immediately before use.
A purity value from one chromatographic method does not capture every possible impurity. Related peptides with similar retention behavior, counterions, and residual solvents may not appear in the same analysis. Independent testing with an orthogonal method provides stronger assurance of identity and content.
Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.